Target intelligence / Profile preview

Chikungunya virus envelope glycoprotein E1 (E1)

Target
E1
Molecular classification
Viral fusion glycoprotein, Class II fusion protein, Envelope glycoprotein
01

Overview

The Chikungunya virus envelope glycoprotein E1 is a class II fusion protein embedded in the virion lipid bilayer, forming heterodimers with E2 (derived from p62 precursor after furin cleavage) that trimerize into 80 icosahedral spikes (T=4 symmetry). It drives low pH-dependent membrane fusion during endosomal entry by exposing its fusion loop (residues 83-100 in domain II), inserting into the host membrane, and trimerizing. E1 also contributes to virus attachment by modulating E1-E2 interactions and binding to glycosaminoglycans like heparin/heparan sulfate, influences receptor interactions (e.g., Mxra8 via E2 changes), stabilizes the glycoprotein lattice through E1-E1 interspike contacts, and supports particle assembly, egress, and immunogenicity. Mutations (e.g., V156A, K211T, M88L, N20Y) alter E2 conformation, cell-type-specific infectivity, GAG binding, antibody neutralization, and pathogenesis in mice and insects.

Other names
Chikungunya virus E1 glycoproteinCHIKV E1p62-E1 heterodimer precursor component (mature form after furin cleavage)
02

Biological functions

Membrane fusion (low pH-triggered in endosomes)Virus attachment (modulates via conformational changes)Glycoprotein lattice stabilization (E1-E1 interspike contacts)Virus entry (facilitates clathrin-mediated endocytosis)Virus egress and particle stability
03

Disease associations

Infection (Chikungunya fever, arthritic disease in humans and mice)Viral pathogenesis (enhanced infectivity and transmission in mammalian and mosquito hosts)

Beyond the preview

Go deeper on Chikungunya virus envelope glycoprotein E1 (E1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chikungunya virus envelope glycoprotein E1 (E1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call